|Bid||0.2900 x 1000|
|Ask||0.3200 x 2200|
|Day's Range||0.2601 - 0.3072|
|52 Week Range||0.2600 - 1.0300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for COCP
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-ascending doses, plans to enroll 56 healthy adults. Results from the first two single-ascending dose 100 mg and 200 mg cohorts showed a favorable pharmacokinetic profile of CC-42344. CC-42344 is an oral PB2 inhibitor that
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...